Patents Assigned to LARIX BIOSCIENCE, LLC
  • Publication number: 20210292384
    Abstract: Disclosed herein are ACE2 fusion proteins that can be used to block infection of cells by SARS-CoV-2. The fusion proteins may have additional functionality such as inhibition of complement. The fusion protein may also include a polypeptide or a moiety that increases serum or blood half-life of the ACE2 fusion protein.
    Type: Application
    Filed: March 19, 2021
    Publication date: September 23, 2021
    Applicant: Larix Bioscience LLC
    Inventors: Bo Yu, James Larrick
  • Patent number: 11060083
    Abstract: The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: July 13, 2021
    Assignee: Larix Bioscience LLC
    Inventors: Bo Yu, James Larrick
  • Publication number: 20210108190
    Abstract: The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.
    Type: Application
    Filed: May 19, 2017
    Publication date: April 15, 2021
    Applicant: LARIX BIOSCIENCE, LLC
    Inventors: Bo Yu, James Larrick
  • Patent number: 10816548
    Abstract: The invention provides a novel cell line development method useful to screen for recombinant protein production. The method utilizes a membrane-anchored reporter or an intracellular reporter residing in the expression vector for a gene of interest to facilitate initial cell selection by FACS or MACS. A switching mechanism can be used to delete the reporter from the chromosome by providing an appropriate DNA recombinase, which turns the selected cells into production cells that secrete the protein of interest without co-expression of the reporter.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: October 27, 2020
    Assignee: Larix Bioscience, LLC
    Inventors: Bo Yu, James Larrick
  • Publication number: 20180334665
    Abstract: The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.
    Type: Application
    Filed: May 19, 2017
    Publication date: November 22, 2018
    Applicant: LARIX BIOSCIENCE, LLC
    Inventors: Bo Yu, James Larrick
  • Publication number: 20180313834
    Abstract: The invention provides a novel cell line development method useful to screen for recombinant protein production. The method utilizes a membrane-anchored reporter or an intracellular reporter residing in the expression vector for a gene of interest to facilitate initial cell selection by FACS or MACS. A switching mechanism can be used to delete the reporter from the chromosome by providing an appropriate DNA recombinase, which turns the selected cells into production cells that secrete the protein of interest without co-expression of the reporter.
    Type: Application
    Filed: February 19, 2018
    Publication date: November 1, 2018
    Applicant: Larix Biosciences LLC
    Inventors: Bo Yu, James Larrick
  • Patent number: 9910038
    Abstract: The invention provides a novel cell line development method useful to screen for recombinant protein production. The method utilizes a membrane-anchored reporter or an intracellular reporter residing in the expression vector for a gene of interest to facilitate initial cell selection by FACS or MACS. A switching mechanism can be used to delete the reporter from the chromosome by providing an appropriate DNA recombinase, which turns the selected cells into production cells that secrete the protein of interest without co-expression of the reporter.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: March 6, 2018
    Assignee: Larix Bioscience, LLC
    Inventors: Bo Yu, James Larrick
  • Patent number: 9663782
    Abstract: The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.
    Type: Grant
    Filed: July 19, 2014
    Date of Patent: May 30, 2017
    Assignee: Larix Bioscience LLC
    Inventors: Bo Yu, James Larrick
  • Publication number: 20150024500
    Abstract: The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.
    Type: Application
    Filed: July 19, 2014
    Publication date: January 22, 2015
    Applicant: LARIX BIOSCIENCE, LLC
    Inventors: Bo Yu, James Larrick
  • Publication number: 20140155285
    Abstract: The invention provides a novel cell line development method useful to screen for recombinant protein production. The method utilizes a membrane-anchored reporter or an intracellular reporter residing in the expression vector for a gene of interest to facilitate initial cell selection by FACS or MACS. A switching mechanism can be used to delete the reporter from the chromosome by providing an appropriate DNA recombinase, which turns the selected cells into production cells that secrete the protein of interest without co-expression of the reporter.
    Type: Application
    Filed: November 27, 2013
    Publication date: June 5, 2014
    Applicant: LARIX BIOSCIENCES LLC
    Inventors: Bo YU, James LARRICK